Please assess the completion status of the following clinical trial:

Trial Title: Does Pantoprazole Reduce the Anti-platelet Effect of Clopidogrel?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients being treated with a maintenance dose of 75 mg clopidogrel and 100 mg aspirin daily after previous PCI with coronary stenting were included in the study. All patients received standardized therapy with a loading dose of 600 mg of clopidogrel hydrogen sulfate and 400 mg aspirin.~All participants had a normal platelet count (150,000-450,000/mL).~Exclusion Criteria:~* Patients with severe liver disorders, current gastrointestinal disorders, a current infection, congestive heart failure, or a known bleeding disorder as well as patients on bivalirudin or glycoprotein IIb/III antagonists within the last 7 days were excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Pantoprazole (Type: ACTIVE_COMPARATOR): Drug: Pantoprazole 40 mg once-daily
- Ranitidine (Type: EXPERIMENTAL): Drug: Ranitidine 150 mg twice-daily

Based on this trial design, predict the completion outcome and termination type (if applicable).